Victoria Blinder
YOU?
Author Swipe
View article: Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast Cancer
Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast Cancer Open
PURPOSE We examined clinician- and facility-level factors associated with selection of nonguideline chemotherapy at treatment initiation in women with stage I-IIIA breast cancer (BC). METHODS The Optimal Breast Cancer Chemotherapy Dosing S…
View article: Provider billing margin and cancer treatment selection: population based cohort study
Provider billing margin and cancer treatment selection: population based cohort study Open
Objective To estimate the association between the billing (profit) margin and clinical benefit of cancer treatments and use by oncologists. Design Retrospective population based cohort study Setting Population based sample using fee-for-se…
View article: Screened but Still Struggling: Challenges in Delivering Financial Assistance After Positive Financial Toxicity Screens
Screened but Still Struggling: Challenges in Delivering Financial Assistance After Positive Financial Toxicity Screens Open
PURPOSE Financial toxicity can negatively affect treatment adherence, quality of life, and survival in patients with cancer. Although screening for financial toxicity is increasingly implemented across oncology practices and cancer centers…
View article: A Randomized Controlled Trial of the Integrated Cancer Care Access Network on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Integrated Cancer Care Access Network on Cancer Treatment Completion and Quality of Life Open
Background: We prospectively examined the effect of a multilingual, multidisciplinary patient navigation and essential needs access program on oncology treatment completion and patient-reported outcomes among medically underserved patients…
View article: Drivers of Job Loss Among Chinese Breast Cancer Survivors: A Qualitative Analysis
Drivers of Job Loss Among Chinese Breast Cancer Survivors: A Qualitative Analysis Open
Purpose This study aimed to understand the reasons for the high risk of job loss previously identified among foreign‐born Chinese breast cancer survivors in the United States Qualitative interviews were conducted to explore challenges lead…
View article: Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer Open
This report describes the rationale, purpose and design of A011801 (CompassHER2 RD), an ongoing prospective, multicenter, Phase III randomized trial. Eligible patients in the United States (US) and Canada with high-risk (defined as ER-nega…
View article: Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®).
Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®). Open
BACKGROUND: We derived meaningful individual-level change thresholds for worsening in selected patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®) items and their composite scores. METHODS: …
View article: A cross-sectional survey to assess breast cancer survivors’ knowledge about lymphedema risk, prevention, and management
A cross-sectional survey to assess breast cancer survivors’ knowledge about lymphedema risk, prevention, and management Open
Background Lymphedema is a common problem that adversely impacts quality of life in breast cancer survivors. Although lymphedema risk is modifiable through behavior change, there is no standardized approach to educate survivors about risk-…
View article: Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®)
Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®) Open
Background We derived meaningful individual-level change thresholds for worsening in selected patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®) items and their composite scores. Methods We…
View article: Measuring Self‐Efficacy to Request Cancer‐Related Work Accommodations: Development and Validation of a Brief Survey Instrument
Measuring Self‐Efficacy to Request Cancer‐Related Work Accommodations: Development and Validation of a Brief Survey Instrument Open
Objective Access to work accommodations, such as time off to attend medical appointments, is a key predictor of cancer‐related job loss. We aimed to develop and validate a measure of self‐efficacy to request and obtain work accommodations …
View article: Data from Patient Characteristics Associated with Intended Nonguideline Chemotherapy in Women with Stage I to IIIA Breast Cancer
Data from Patient Characteristics Associated with Intended Nonguideline Chemotherapy in Women with Stage I to IIIA Breast Cancer Open
Background:Guidelines informing chemotherapy regimen selection are based on clinical trials with participants who do not necessarily represent general populations with breast cancer. Understanding who receives nonguideline regimens is impo…
View article: Supplementary Table 1 from Patient Characteristics Associated with Intended Nonguideline Chemotherapy in Women with Stage I to IIIA Breast Cancer
Supplementary Table 1 from Patient Characteristics Associated with Intended Nonguideline Chemotherapy in Women with Stage I to IIIA Breast Cancer Open
Supplementary Table 1. Association between patient factors and guideline chemotherapy administered outside of period in which regimens were included in the guidelines
View article: Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I–<scp>IIIA</scp> breast cancer
Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I–<span>IIIA</span> breast cancer Open
For patients with breast cancer, delays in chemotherapy initiation have been adversely associated with recurrence and survival. We evaluated patient‐level factors associated with delayed chemotherapy initiation, from both diagnosis and sur…
View article: Breast Cancer-Related Employment Disruption and Financial Hardship in the Sister Study
Breast Cancer-Related Employment Disruption and Financial Hardship in the Sister Study Open
Background: More than one-half of breast cancer cases are diagnosed among women aged younger than 62 years, which may result in employment challenges. This study examined whether cancer-related employment disruption was associated with inc…
View article: Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline <i>BRCA1/2</i> Mutations
Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline <i>BRCA1/2</i> Mutations Open
Importance The OlympiA trial found that 1 year of adjuvant olaparib therapy can improve distant disease-free survival and overall survival from early-stage breast cancer in patients with a germline BRCA1/2 mutation. However, olaparib, an o…
View article: Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39)
Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39) Open
PURPOSE Financial toxicity (FT) affects 20% of cancer survivors and is associated with poor clinical outcomes. No large-scale programs have been implemented to mitigate FT. We evaluated the effect of monthly FT screening as part of a large…
View article: Supplementary Table S3 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Table S3 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Summary of changes in immune cell subsets from baseline to Cycle 1 Day 8 after LY3022855 treatment.
View article: Supplementary Figure S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Figure S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Time plots of circulating levels of interleukin-34
View article: Supplementary Materials and Methods from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Materials and Methods from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Dose selection details, T cell activation/exhaustion flow assay and multiplex cytokine measurements.
View article: Supplementary Table S1 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Table S1 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Best overall response by RECIST 1.1 and PCWG2 for bone.
View article: Supplementary Table S4 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Table S4 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Relationship between confounding factors and response (RECIST).
View article: Supplementary Table S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Supplementary Table S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study Open
Summary of noncompartmental pharmacokinetic parameters following intravenous infusion of LY3022855.